In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news from Washington with guest Mark Leahey.

• Welcome to the Eyeluminaries podcast :02
• Review of episode 31 :40
• BVI Medical names a new CCO 2:20
• GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions 5:42
• Tenpoint submits new drug application for presbyopia combination therapy 7:33
• Alcon acquires majority stake in Aurion Biotech 10:29
• FDA approves Encelto for macular telangiectasia type 2 14:50
• Intro of Mark Leahey 17:28
• There is a lot of attention on the HHS restructuring. What are your insights into what has happened to date, and what could happen in the future? 20:10
• What do you think about the leadership? 23:44
• Let’s talk about sustainability. Tell us about the medical device industry’s collective interest and challenges in regard to moving toward environmentally sustainable initiatives. 24:59
• Let’s talk about leadership: Dr. Marty Makary and Dr. Oz. 27:53
• Tariffs are an evolving subject. What is the impact on the medical community? What is your impression on how these will affect us in the short term and long term? 33:20
• Preview of episode 33 39:27
• Give us your feedback 40:23
• Team Mah-rvel: the Party for a Purpose 40:41
• Thanks 40:58

John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Mark Leahey is the president and CEO for the Medical Device Manufacturers Association (MDMA).

Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.

We’d love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.

Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Leahey.